Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer.

J Li, J Wang, X Hao, X Zhang… - Chinese Journal of Lung …, 2012 - search.ebscohost.com
Background and objective Pemetrexed is a standard second-line therapy in advanced non-
small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy …
被引用次数：3 相关文章

Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer

J Li, J Wang, X Hao, X Zhang, Y Shi - … fei ai za zhi= Chinese Journal …, 2012 - europepmc.org
Methods Clinical data on 37 patients with advanced NSCLC who received pemetrexed as
second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from …

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients with Advanced Non-small Cell Lung Cancer

LI Junling, W Jing, HAO Xuezhi, X ZHANG… - Zhongguo Fei Ai …, 2012 - search.proquest.com
背景与目的培美曲塞是晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)
推荐的标准二线治疗方案之一. 目前二线治疗之后如何选择化疗药物尚无标准 …

Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer

J Li, J Wang, X Hao, X Zhang… - Zhongguo fei ai za zhi …, 2012 - pubmed.ncbi.nlm.nih.gov
Background and objective Pemetrexed is a standard second-line therapy in advanced non-
small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy …

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients with Advanced Non-small Cell Lung Cancer.

J LI, J WANG, X HAO, X ZHANG… - Chinese Journal of Lung …, 2012 - search.ebscohost.com
Background and objective Pemetrexed is a standard second-line therapy in advanced non-
small cell lung cancer (NSCLC). Currently, cytotoxic treatments beyond second-line therapy …

Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer

J Li, J Wang, X Hao, X Zhang, Y Shi - … fei ai za zhi= Chinese Journal …, 2012 - europepmc.org
Methods Clinical data on 37 patients with advanced NSCLC who received pemetrexed as
second-line therapy or beyond in Cancer Hospital of Peking Union Medical College from …